ArticleJournal of medicinal chemistry2020

Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.

Huiyu Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.